Crispr Theraptc (NASDAQ:CRSP) released its quarterly earnings results on Thursday. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.06, Briefing.com reports. The firm had revenue of $3.60 million for the quarter, compared to the consensus estimate of $3.29 million. Crispr Theraptc’s revenue for the quarter was up 350.0% on a year-over-year basis.

Crispr Theraptc (NASDAQ:CRSP) traded up 7.98% during trading on Friday, hitting $19.22. The stock had a trading volume of 577,867 shares. The stock’s market cap is $768.74 million. Crispr Theraptc has a 12 month low of $11.63 and a 12 month high of $25.00. The firm has a 50 day moving average of $17.00 and a 200-day moving average of $17.49.

In other news, Director Kurt Von Emster sold 81,435 shares of Crispr Theraptc stock in a transaction on Tuesday, June 27th. The shares were sold at an average price of $17.08, for a total transaction of $1,390,909.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Rodger Novak sold 50,000 shares of Crispr Theraptc stock in a transaction on Wednesday, May 17th. The stock was sold at an average price of $16.26, for a total transaction of $813,000.00. Following the sale, the chief executive officer now owns 1,239,082 shares of the company’s stock, valued at $20,147,473.32. The disclosure for this sale can be found here. Insiders have sold 543,814 shares of company stock valued at $9,232,047 over the last quarter. Insiders own 39.98% of the company’s stock.

A hedge fund recently bought a new stake in Crispr Theraptc stock. Vanguard Group Inc. acquired a new stake in Crispr Theraptc (NASDAQ:CRSP) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 17,019 shares of the company’s stock, valued at approximately $273,000. Institutional investors and hedge funds own 24.08% of the company’s stock.

Several equities analysts have recently weighed in on CRSP shares. SunTrust Banks, Inc. started coverage on Crispr Theraptc in a report on Thursday, July 13th. They set a “hold” rating and a $16.00 price target on the stock. Cann started coverage on Crispr Theraptc in a report on Monday, July 17th. They set a “market perform” rating on the stock. Finally, Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Crispr Theraptc in a report on Tuesday, July 18th. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Crispr Theraptc has an average rating of “Buy” and an average target price of $21.92.

WARNING: This story was originally published by Daily Political and is owned by of Daily Political. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/08/11/crispr-theraptc-nasdaqcrsp-releases-quarterly-earnings-results-beats-estimates-by-0-06-eps.html.

About Crispr Theraptc

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with MarketBeat.com's FREE daily email newsletter.